<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00915057</url>
  </required_header>
  <id_info>
    <org_study_id>NRL972-09/2008 (CHBC)</org_study_id>
    <nct_id>NCT00915057</nct_id>
  </id_info>
  <brief_title>Effect of Chronic Viral Hepatitis on the Pharmacokinetics of NRL972.</brief_title>
  <official_title>An Open Study to Investigate the Effects of Chronic Viral Hepatitis B or C on the Pharmacokinetics of Cholyl-lysyl-fluorescein (NRL972) Before, During and After Standard Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norgine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Norgine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Little is known about the nature and extent of the disturbance in hepatic function and&#xD;
      biliary hepatic clearance in chronic viral hepatitis, while the course of this disease, the&#xD;
      functional implications and response to treatment are difficult to predict. This study aims&#xD;
      to assess this in patients with chronic viral hepatitis B (CHB) and chronic viral hepatitis C&#xD;
      (CHC) who are eligible for treatment in accordance with the established consensus guidelines&#xD;
      in the involved countries. The pharmacokinetics of NRL972 will be determined at baseline&#xD;
      (within one month of starting treatment), at 3-monthly intervals during treatment, for up to&#xD;
      12 months (or at the end of treatment), and at 3 and 6 months after the end on treatment.&#xD;
      This will provide a clearer understanding regarding the use of the pharmacokinetics of NRL972&#xD;
      in detecting changes in biliary clearance during and after treatment for CHB and CHC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of NRL972</measure>
    <time_frame>Up to one hour post-dosing</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatitis, Viral, Human</condition>
  <arm_group>
    <arm_group_label>NRL972</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 2mg intravenous dose of NRL972, administered on up to seven occasions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRL972</intervention_name>
    <description>Single dose of NRL972 administered at baseline, at 3-monthly intervals during treatment for up to 12 months (or the end of treatment) and at 3 and 6 months after the end of treatment.</description>
    <arm_group_label>NRL972</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Chronic viral hepatitis B&#xD;
&#xD;
          -  Adult, male or female, age ≥ 18 years and &lt; 65 years&#xD;
&#xD;
          -  Body weight (BW) : 45 - 110 kg&#xD;
&#xD;
          -  Body mass index (BMI) : 18 - 30 kg.m-2&#xD;
&#xD;
          -  HBV Serology: HBsAg+ for ≥ 6 months (at the time of application for treatment)&#xD;
&#xD;
          -  Serum ALT ≥ 1.5 times ULN ≥ 6 months (at the time of application for treatment)&#xD;
&#xD;
          -  Positive liver biopsy within 24 months before screening visit&#xD;
&#xD;
          -  Positive biopsy with signs of active disease (any level of activity by Knodell,&#xD;
             METAVIR or ISHAK)&#xD;
&#xD;
          -  HBV DNA counts determined by quantitative PCR: ≥ 20,000 IU/mL ALT &lt; 10 times ULN&#xD;
&#xD;
          -  HIV-Ab negative&#xD;
&#xD;
          -  Non-cirrhotic liver disease (on histology within 24 months before screening visit)&#xD;
&#xD;
          -  Not having been treated for chronic viral hepatitis previously (&quot;de novo&quot; i.e.&#xD;
             &quot;naïve&quot;)&#xD;
&#xD;
          -  Eligible for treatment of chronic viral hepatitis in accordance with the national&#xD;
             consensus guidelines pertinent to the country and site of conduct of the trial&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
        Chronic viral hepatitis C&#xD;
&#xD;
          -  Adult, male or female, age ≥ 18 years and &lt; 65 years&#xD;
&#xD;
          -  Body weight (BW) : 45 - 110 kg&#xD;
&#xD;
          -  Body mass index (BMI) : 18 - 30 kg.m-2&#xD;
&#xD;
          -  HCV-Ab+ for ≥ 6 months (at the time of application for treatment)&#xD;
&#xD;
          -  HCV RNA counts &gt; 10,000 U/L by quantitative PCR assay within the last 6 months (at the&#xD;
             time of application for treatment)&#xD;
&#xD;
          -  Positive liver biopsy within 24 months before application for treatment&#xD;
&#xD;
          -  Positive biopsy with signs of fibrotic disease (levels of fibrosis METAVIR ≥ F1 or&#xD;
             ISHAK ≥ F2)&#xD;
&#xD;
          -  ALT &lt; 10 times ULN&#xD;
&#xD;
          -  HIV-Ab negative&#xD;
&#xD;
          -  Non-cirrhotic liver disease (on histology within 24 months before screening visit)&#xD;
&#xD;
          -  Not having been treated for chronic viral hepatitis previously (&quot;de novo&quot; i.e.&#xD;
             &quot;naïve&quot;)&#xD;
&#xD;
          -  Eligible for treatment of chronic viral hepatitis in accordance with the national&#xD;
             consensus guidelines pertinent to the country and site of conduct of the trial&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
        Chronic viral hepatitis C plus chronic viral hepatitis B&#xD;
&#xD;
          -  Patients with combined CHB and CHC will be managed (in terms of eligibility and&#xD;
             standard treatment in accordance with the hepatitis type with predominant viral&#xD;
             replication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Trial specific criteria: CHB, CHC &amp; CHB+CHC&#xD;
&#xD;
          -  Previous participation in the trial&#xD;
&#xD;
          -  Participation in any other clinical trial within 30 days of entry to this protocol&#xD;
&#xD;
          -  Treatment with any investigational drug within 30 days of entry to this protocol&#xD;
&#xD;
          -  Non-response to previous treatment for chronic viral hepatitis&#xD;
&#xD;
          -  Relapse after previous treatment for chronic viral hepatitis&#xD;
&#xD;
          -  Any other known cause of liver disease other than chronic viral hepatitis B and/or C,&#xD;
             including but not limited to hepatitis D, haemochromatosis, alpha1-antitrypsin&#xD;
             deficiency, Wilson's disease, autoimmune hepatitis, drug-related liver disease&#xD;
&#xD;
          -  Evidence of advanced liver disease, such as history or presence of ascites, bleeding&#xD;
             varices, encephalopathy&#xD;
&#xD;
          -  Patients with organ transplants&#xD;
&#xD;
          -  Hypersensitivity to prospective standard treatment&#xD;
&#xD;
          -  Any relevant co-morbidity, for instance, but not limited to:&#xD;
&#xD;
          -  Limiting uncompensated psychiatric condition (e.g. severe depression, or a history of&#xD;
             severe psychiatric disorder)&#xD;
&#xD;
          -  CNS trauma or seizure disorder requiring medication&#xD;
&#xD;
          -  Significant cardiovascular dysfunction within the past 6 months (e.g. angina,&#xD;
             congestive cardiac failure, recent myocardial infarction, severe hypertension or&#xD;
             significant arrhythmia)&#xD;
&#xD;
          -  Patients with an ECG showing clinically significant abnormalities&#xD;
&#xD;
          -  Poorly controlled diabetes mellitus&#xD;
&#xD;
          -  Patients on haemodialysis&#xD;
&#xD;
          -  Daily use of &gt; 40 g alcohol&#xD;
&#xD;
          -  Positive alcohol test at SCR-visit&#xD;
&#xD;
          -  Evidence or suspicion of social drug abuse&#xD;
&#xD;
          -  Positive drug test at SCR-visit&#xD;
&#xD;
          -  Use of prohibited medication&#xD;
&#xD;
          -  Suspicion or evidence that the subject is not trustworthy and reliable&#xD;
&#xD;
          -  Suspicion or evidence that the subject is not able to make a free consent or to&#xD;
             under-stand the information in this regard&#xD;
&#xD;
        Criteria specifically related to the standard treatment of chronic viral hepatitis&#xD;
&#xD;
          -  Relevant clinical laboratory test abnormalities, for instance, but not limited to:&#xD;
&#xD;
        Haemoglobin (Hgb) &lt;11 g dL-1 for women and &lt;13 g dL-1 for men&#xD;
&#xD;
        White Blood Cell count (WBC) &lt; 3,000 10 exp9/mL&#xD;
&#xD;
        Granulocyte count &lt; 1,500 10 exp9/mL&#xD;
&#xD;
        Lymphocyte count &lt; 500 10 exp9/mL&#xD;
&#xD;
        Platelets &lt; 75,000 10 exp9/mL&#xD;
&#xD;
        Prothrombin time - INR &gt; 1.4&#xD;
&#xD;
        Bilirubin &gt; 25 micromol/L (except in functional hyperbilirubinaemia)&#xD;
&#xD;
        Albumin &lt; 35 g/L&#xD;
&#xD;
        Serum creatinine &gt; 133 micromol/L&#xD;
&#xD;
        Fasting blood glucose &gt; 7.4 mmol/L for non-diabetic patients&#xD;
&#xD;
        HbA1c &gt; 7% for diabetic patients&#xD;
&#xD;
        Positive auto-immune antibodies&#xD;
&#xD;
        TSH outside the normal range (for patients intended for interferon)&#xD;
&#xD;
          -  Relevant co-morbidity, for instance, but not limited to:&#xD;
&#xD;
        Limiting uncompensated chronic pulmonary disease (e.g. chronic obstructive pulmonary&#xD;
        disease)&#xD;
&#xD;
        Any medical condition requiring, or likely to require during the course of the study,&#xD;
        chronic systemic administration of steroids&#xD;
&#xD;
        Gout - (for patients intended for interferon)&#xD;
&#xD;
        Immunologically mediated disease (e.g. inflammatory bowel disease, Crohn's disease,&#xD;
        ulcerative colitis, rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic&#xD;
        lupus erythematosus, autoimmune haemolytic anaemia, scleroderma, severe psoriasis,&#xD;
        cryoglobulinaemia with vasculitis) - (for patients intended for interferon)&#xD;
&#xD;
        Patients with clinically significant retinal abnormalities - (for patients intended for&#xD;
        interferon)&#xD;
&#xD;
        All females&#xD;
&#xD;
          -  Positive pregnancy test&#xD;
&#xD;
          -  Lactating&#xD;
&#xD;
          -  Not using medically appropriate contraception and/or not willing to maintain such&#xD;
             contraception during the treatment of chronic viral hepatitis and up to 6 months&#xD;
             thereafter&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-Jürgen Gruss, MD</last_name>
    <role>Study Director</role>
    <affiliation>Norgine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MHAT Sveti Ivan Rilski EAD</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Institute Fundeni</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency Country Hospital Cluj</name>
      <address>
        <city>Cluj</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Clinic Algomed SRL</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>June 3, 2009</study_first_submitted>
  <study_first_submitted_qc>June 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2009</study_first_posted>
  <last_update_submitted>December 21, 2009</last_update_submitted>
  <last_update_submitted_qc>December 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>Vice President Clinical Development</name_title>
    <organization>Norgine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Viral, Human</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

